** Citi upgrades CME to "buy" from "hold," citing catalysts ahead
** Brokerage sees a robust capital return over the next four months as it expects CME to return proceeds from OSSTRA sale to shareholders
** Adds CME's joint venture with FanDuel should help the firm expand its retail presence
** 6 of 18 brokerages rate the stock "buy" or higher, 9 "hold" and 3 "sell"; median PT $285 - data compiled by LSEG
** As of last close, CME stock up 14% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.